Cancer Research Cancer Medicine 8 EMT and Cancer Progression and Treatment
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Cancer Research 66, 10541, November 1, 2006. doi: 10.1158/0008-5472.CAN-06-1573
© 2006 American Association for Cancer Research
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Malfatti, M. A.
Right arrow Articles by Turteltaub, K. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Malfatti, M. A.
Right arrow Articles by Turteltaub, K. W.

Experimental Therapeutics, Molecular Targets, and Chemical Biology

The Urinary Metabolite Profile of the Dietary Carcinogen 2-Amino-1-Methyl-6-Phenylimidazo[4,5-b]Pyridine Is Predictive of Colon DNA Adducts after a Low-Dose Exposure in Humans

Michael A. Malfatti1, Karen H. Dingley1, Susan Nowell-Kadlubar2, Esther A. Ubick1, Nisha Mulakken1, David Nelson1, Nicholas P. Lang2,3, James S. Felton1 and Kenneth W. Turteltaub1

1 Lawrence Livermore National Laboratory, Livermore, California and 2 University of Arkansas for Medical Sciences; 3 Central Arkansas Veterans Healthcare System, Little Rock, Arkansas

Requests for reprints: Michael A. Malfatti, Lawrence Livermore National Laboratory, 7000 East Avenue, L452, Livermore, CA 94550. Phone: 925-422-5732; Fax: 925-422-2282; E-mail: malfatti1{at}llnl.gov.


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Epidemiologic evidence indicates that exposure to heterocyclic amines in the diet is an important risk factor for the development of colon cancer. Well-done cooked meats contain significant levels of heterocyclic amines, which have been shown to cause cancer in laboratory animals. To better understand the mechanisms of heterocyclic amine bioactivation in humans, the most mass abundant heterocyclic amine, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP), was used to assess the relationship between PhIP metabolism and DNA adduct formation. Ten human volunteers where administered a dietary relevant dose of [14C]PhIP 48 to 72 hours before surgery to remove colon tumors. Urine was collected for 24 hours after dosing for metabolite analysis, and DNA was extracted from colon tissue and analyzed by accelerator mass spectrometry for DNA adducts. All 10 subjects were phenotyped for cytochrome P4501A2 (CYP1A2), N-acetyltransferase 2, and sulfotransferase 1A1 enzyme activity. Twelve PhIP metabolites were detected in the urine samples. The most abundant metabolite in all volunteers was N-hydroxy-PhIP-N2-glucuronide. Metabolite levels varied significantly between the volunteers. Interindividual differences in colon DNA adducts levels were observed between each individual. The data showed that individuals with a rapid CYP1A2 phenotype and high levels of urinary N-hydroxy-PhIP-N2-glucuronide had the lowest level of colon PhIP-DNA adducts. This suggests that glucuronidation plays a significant role in detoxifying N-hydroxy-PhIP. The levels of urinary N-hydroxy-PhIP-N2-glucuronide were negatively correlated to colon DNA adduct levels. Although it is difficult to make definite conclusions from a small data set, the results from this pilot study have encouraged further investigations using a much larger study group. (Cancer Res 2006; 66(21): 10541-7)


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Humans are constantly exposed to a wide range of chemical carcinogens in their environment. One of the most significant sources of environmental exposure is through the diet (1). Heterocyclic amines, formed during the cooking of muscle meats, have been determined to be mutagenic in standard test systems and carcinogenic in animal models (2). These compounds are found in concentrations of up to 500 ppb in foods commonly consumed in a typical Western diet. 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP), the most mass abundant heterocyclic amine found in well-done cooked chicken and beef (3, 4), has been shown to cause colon, mammary, and prostate tumors in rats, lymphomas in mice, and hepatic adenomas in neonatal mice (5–8). In humans, epidemiology studies have indicated an increased risk of colon and breast tumors associated with PhIP exposure from well-done red meat consumption (9, 10). PhIP has also been designated as "reasonably anticipated to be a human carcinogen" by the National Toxicology Program. These findings, together with the relative abundance of PhIP in cooked foods, suggest that exposure to PhIP is a significant cancer risk factor for humans.

Heterocyclic amines require metabolic activation to a bioreactive species before they can interact with DNA to form adducts. The bioactivation of PhIP to its carcinogenic form is highly dependent on the cytochrome P4501A2 (CYP1A2)-mediated hydroxylation of the exocyclic amine group to form the corresponding 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5-b]pyridine (N-hydroxy-PhIP; refs. 11, 12). Subsequent esterification by sulfotransferases and/or acetyltransferases generates the highly electrophilic O-sulfonyl and O-acetyl esters, respectively. These esters are capable of covalently binding DNA (13, 14). N-hydroxy-PhIP can also form the less reactive glucuronide conjugates at the N2 amine nitrogen or the N3 ring nitrogen, which can be excreted through the urine or bile or be transported to other tissue where further metabolism can occur (15, 16). This pathway is a predominant step in the biotransformation of PhIP in humans (17).

Studies have shown that the rate of heterocyclic amine metabolism can be influenced by enzyme phenotype and/or genotype. A correlation between CYP1A2 activity levels and urinary excretion of heterocyclic amine metabolites was observed in human populations fed well-done cooked meat. High levels of CYP1A2 activity were associated with reduced levels of unmetabolized PhIP in the urine, indicating that more PhIP is being converted to the bioactive N-hydroxy derivative compared with urinary heterocyclic amine levels from individuals with low CYP1A2 activity (18–20). In addition, polymorphisms in the UDP-glucuronosyltransferase 1A1 (UGT1A1) gene were associated with a decreased ability to detoxify N-hydroxy-PhIP via glucuronidation in human liver samples due to reduced UGT1A1 activity (21).

Enzyme polymorphisms can lead to interindividual variation in DNA adduct formation as well. A positive correlation was reported between the level of DNA adducts and the level of CYP1A2 activity in human liver microsomes incubated with PhIP. As CYP1A2 activity increased, there was a concomitant increase in PhIP-DNA adduct levels, suggesting that DNA adducts can be used as an indicator of interindividual variability in the metabolic activation of heterocyclic amines (22). Furthermore, increases in bioactivation and DNA adduct formation due to phenotypic differences in CYP1A2 and N-acetyltransferase 2 (NAT2) activity have been implicated as increased colon cancer risk factors associated with heterocyclic amine exposure (23). Therefore, susceptibility to the carcinogenic risks associated with heterocyclic amine exposure can depend on exposure levels as well as specific enzyme phenotypes that can affect the bioactivating capacity of certain metabolizing enzymes.

The relationship between PhIP-DNA adduct formation, metabolism, and exposure has been primarily established at high PhIP doses using animal models, mostly due to limitations in assay sensitivity and the difficulties associated with human in vivo studies. In the present study, these limitations have been overcome by using accelerator mass spectrometry (AMS), which is capable of accurately measuring attomole (10–18) quantities of radiolabeled compound (24, 25). The goal of the current study is to determine the relationship between PhIP metabolism, DNA adduct levels, and enzyme phenotype in humans at a dietary relevant dose of PhIP and to determine if metabolite levels and/or enzyme phenotype can predict interindividual susceptibility to DNA adduct formation.

AMS was used to measure colon DNA adducts in a human population exposed to a dietary equivalent dose of PhIP, labeled with a very low level of 14-carbon. The 0.011 mSv radioactive dose each subject received is equivalent to 1/29 of the energy received from an average chest X-ray. Urinary PhIP metabolite levels and selected enzyme phenotypes were also assessed in an effort to establish a link between metabolite levels, enzyme phenotype, and DNA adducts. Data are presented that suggest that urinary PhIP metabolite profiles can serve as a biomarker to predict interindividual differences in DNA adduct levels at dose levels that are typical of human exposure conditions. This pilot study should provide a better understanding of the critical role each metabolic step has in the bioactivation and detoxification of this carcinogen. Ultimately, an assessment of individual susceptibility to the potential cancer risks from PhIP exposure should be possible.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Chemicals. [2-14C]PhIP was obtained from Toronto Research Chemicals (North York, Ontario, Canada). After repurification, the chemical purity was >99% and the radiopurity was >95%. Qiagen tip-500 anion exchange columns for DNA extractions were obtained from Qiagen (Valencia, CA). Proteinase K, RNase A, and RNase T1 were purchased form Sigma Chemical Co. (St. Louis, MO). All other reagents were of analytic grade or better.

Human study. The human study protocol was independently reviewed and approved by the Institutional Review Boards for Human Subjects at the Lawrence Livermore National Laboratory (Livermore, CA), the University of Arkansas Medical School Hospital (Little Rock, AR), and the John L. McClellan Memorial Veterans Administration Medical Center (Little Rock, AR). Details of the study protocol are reported elsewhere (26). Briefly, 10 human volunteers were recruited for the study. All volunteers were cancer patients undergoing surgery to remove colon carcinoma(s) and gave informed consent before enrollment. The study population consisted of nine Caucasian males and one Caucasian female ranging in age from 44 to 82 years. [14C]PhIP was administered orally in a gelatin capsule before surgery. Subjects 1 and 2 received a dose of 70 µg [14C]PhIP per person (specific activity, 56 mCi/mmol), and subjects 3 to 10 received a dose of 84 µg [14C]PhIP (specific activity, 41.8 mCi/mmol). The differences in the amounts and the specific activity of [14C]PhIP were a result of preparing the PhIP capsules on two different occasions from two batches of [14C]PhIP.

Urinary metabolite characterization. Urine was collected at various time points up to 24 hours after [14C]PhIP exposure and then frozen at –20°C until processing for metabolite analysis. Details of the urinary metabolite analysis have been previously reported (17). Briefly, an aliquot of each urine sample containing approximately 6,000 to 8,000 dpm was analyzed by high-performance liquid chromatography (HPLC) for PhIP and PhIP metabolites. Each sample was directly injected into a Rainin HPLC system (Varian, Walnut Creek, CA) equipped with a 5-µm, 4.6 x 220–mm TSK-GEL ODS-80 TM column (TosoHaas, Montgomeryville, PA) and monitored at 315 nm. The column eluate was collected at 1-minute intervals, and radioactivity was quantified by scintillation counting (Wallac, Gaithersburg, MD). Metabolites were identified by coelution with authentic PhIP metabolite standards and by mass spectral characterization (17). For mass spectral analysis, each isolated metabolite was directly injected into a Michrom µLC system (Michrom Bioresources, Inc., Auburn, CA) equipped with a Zorbax C18 SB column (0.2 x 150 mm; Michrom Bioresources) and coupled to a Finnigan MAT TSQ-700 triple quadrupole mass spectrometer through a Finnigan electrospray interface (Finnigan MAT, San Jose, CA). Full scan and collision-induced dissociation mass spectra were obtained for each metabolite using previously described variables (17).

Tissue collection and DNA extraction. Forty-eight to 72 hours after dosing, the volunteers underwent surgery for a partial colonectomy. Colon tissue not required for diagnosis or staging was collected and frozen at –80°C until analysis. DNA and protein were extracted from the colon tissue and analyzed by AMS for PhIP-DNA adduct formation using previously reported methods (26, 27).

Enzyme phenotyping. Blood was collected before [14C]PhIP dosing for phenotyping sulfotransferase 1A1 (SULT1A1) activity. Separation of platelets and preparation of cytosol for SULT1A1 phenotyping have been described previously (28). Phenotyping for CYP1A2 and NAT2 was done preoperatively or postoperatively using the caffeine phenotyping assay (29, 30).

Statistical analysis. Two statistical approaches were used to analyze the data. The first used univariate linear modeling and stepwise variable selection using the Akaike Information Criterion method. These parametric methods were used because of the small number of degrees of freedom (df, 9) available in this study. There were 26 variables but only 10 observations in the study. Because the degrees of freedom in a linear model are df = n – p, where n is the number of observations and p is the number of variables, a model, including all 26 variables, could not be fitted.

The second approach used the nonparametric random forest regression analysis, which is a test to determine the importance of one variable in relation to another. This method ranks all variables in a study in the order of importance. The importance measure, which is the percentage increase in mean squared error (MSE), is calculated for each variable. Each variable is then randomly shuffled across observations, whereas all other variables are left as is. The new MSE is calculated using the random forest regression algorithm. If the variable in question is an important predictor of the outcome (i.e., DNA adducts), the new calculated MSE will be higher than the original MSE. The larger the percentage increase in MSE, the more important the variable is as a predictor of outcome.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Urinary metabolite analysis. All 10 volunteers produced 12 radioactive metabolite peaks associated with PhIP from the first 24 hours of collected urine. Identification of the major urinary PhIP metabolites from a subset of these individuals has been previously reported (17). Six of the 12 metabolites were identified as PhIP-glucuronide conjugates. In all 10 subjects, the amount of PhIP-glucuronide metabolites accounted for 60% to 85% of the total metabolites recovered over the 24-hour collection time (Table 1 ), indicating that in humans glucuronidation is a major pathway in the biotransformation of PhIP.


View this table:
[in this window]
[in a new window]
  		Table 1. PhIP metabolites recovered from human urine over 24 hours after a [14C]PhIP dose

 
The most abundant PhIP metabolite in all 10 volunteers was determined to be N-hydroxy-PhIP-N2-glucuronide. The total amount of this metabolite varied greatly between individuals, accounting for 37% to 62% of the total amount of recovered urinary metabolites over the 24-hour collection time (Table 1). The percentage of this metabolite excreted in the urine over time also varied significantly between each subject (Fig. 1 ). In five of the 10 subjects, >45% of N-hydroxy-PhIP-N2-glucuronide was excreted in the first 4 hours after PhIP dosing, with subject 4 being the highest at 63% excreted in 4 hours. Subject 2 had the lowest at 19% excreted in 4 hours. The first three metabolites listed in Table 1 (all of which have been tentatively identified as PhIP-glucuronide conjugates) displayed a wide range of variability between the 10 subjects as well, each accounting for 0.6% to 8% of the total amount of recovered metabolites. No other metabolites displayed such a wide range of variability between the subjects. Interestingly, in subjects where N-hydroxy-PhIP-N2-glucuronide was present at >50% of the total recovered metabolites, the cumulative total of the first three metabolites was <7% of the total recovered metabolites, whereas when N-hydroxy-PhIP-N2-glucuronide levels were <50% of the total recovered metabolites, the cumulative total of the three metabolites ranged from 8% to 20% (Table 1). These results suggest that the enzymes involved in catalyzing the formation of these metabolites may be in competition with each other for substrate.


Figure 1
View larger version (13K):
[in this window]
[in a new window]
  		Figure 1. Percentage of N-hydroxy-PhIP-N2-glucuronide excreted in human urine after an oral [14C]PhIP dose. Columns, amount of N-hydroxy-PhIP-N2-glucuronide excretion at each time point expressed as a percentage of total N-hydroxy-PhIP-N2-glucuronide excreted over a 24-hour period; bars, SD. The urine from each subject was analyzed thrice. For subject 1, the collection times were 0 to 4, 4 to 12, and 12 to 24 hours. For subject 2, the collection times were 0 to 4, 4 to 17.5, and 17.5 to 33 hours.

 
DNA and protein adduct analysis. The levels of covalently bound [14C]PhIP in colon DNA and protein and total 14C levels in whole tissue are presented in Table 2 . Interindividual differences were evident in the amount of PhIP bound to all three tissue fractions. There was no correlation, however, between the binding levels of PhIP in DNA and the levels in the protein or tissue within each individual. Only subject 6 displayed a consistent binding pattern, having the highest level of [14C]PhIP in DNA, total protein, and whole tissue compared with the rest of the study group. Blood albumin was also collected and assessed for covalent binding of [14C]PhIP. There was no correlation between albumin adducts and the colon DNA, protein, or tissue adducts (data not shown).


View this table:
[in this window]
[in a new window]
  		Table 2. Covalent binding of [14C]PhIP to colon DNA and protein and total 14C levels in whole tissue

 
Phenotype/genotype analysis. Each subject was phenotyped for CYP1A2, NAT2, and SULT1A1 enzyme activity. All of which are involved in PhIP metabolism. Table 3 shows the phenotypic activity levels for CYP1A2, NAT2, and SULT1A1 for the 10 subjects. The CYP1A2 and NAT2 activities estimated from the caffeine metabolism phenotyping assay showed a dichotomized distribution. CYP1A2 activity levels >10 were categorized as having a rapid CYP1A2 phenotype, and values <10 were considered a slow metabolizer, based on the analysis of the caffeine metabolite ratios (31). Subject 4 had the highest CYP1A2 activity with a value nearly thrice higher than the next highest value in subject 1. The NAT2 values were also divided into two groups: a slow group with caffeine metabolite ratios <0.7 and a fast group with ratios >0.7 (31). Based on this criterion, subjects 1, 4, 5, 6, 9, and 10 were labeled as having a rapid NAT2 phenotype. Only two subjects (subjects 6 and 8) were considered to have fast SULT1A1 activity levels when the phenotype values were dichotomized at 1.0 nmol/min/mg protein (32).


View this table:
[in this window]
[in a new window]
  		Table 3. CYP1A2, NAT2, and SULT1A1 phenotype data

 
To determine if the observed variations in metabolism and DNA adducts were due to variations in UGT1A1 expression, each individual was genotyped for the UGT1A1*28 polymorphism. This polymorphism results in significant down-regulation of UGT1A1 activity and is characterized by an additional TA repeat in the A(TA)nTAA box region of the promoter. The dominant allele contains six repeats, whereas the variant alleles have seven repeats. Subjects 2, 3, 5, 7, 8, 9, and 10 were heterozygous (6 of 7) for the "A(TA)nTAA" repeat. Subjects 2 and 6 were homozygous wild-type (6 of 6). Subject 1 was not tested. Previous studies have shown that there is no significant difference in UGT1A1 activity between the wild-type and the heterozygous variant (33, 34). Only individuals possessing the homozygous variant (7 of 7) display significant down-regulation of UGT1A1 activity.

Statistical analysis. Data obtained from the metabolite analysis, enzyme phenotype, and PhIP-DNA adduct data sets were analyzed by various statistical methods to determine if any of the measured variables were correlated to colon DNA adducts. There were 26 variables that were considered for this analysis. Both univariate and nonparametric models were used to evaluate the data. Because there were 26 variables but only 9 degrees of freedom, it was not possible to fit a full univariate linear model to include all the variables. Therefore, a univariate linear analysis was done for each variable and the Ps were compared from each analysis. Table 4 shows the univariate linear model results for all the variables. N-hydroxy-PhIP-N2-glucuronide, unknown metabolite 3, and CYP1A2 activity had the lowest Ps, indicating that these variables are the most significantly (P < 0.05) correlated to colon DNA adducts. However, the low level and the lack of significant variation in unknown metabolite 3 between each subject deemed this metabolite not useful for predicting DNA adducts. N-hydroxy-PhIP-N2-glucuronide was determined to be the best predictor of colon DNA adducts. Because of the low degrees of freedom due to the small sample set, the data were independently reevaluated using the nonparametric random forest analysis. Although this is a less robust test compared with the univariate analysis, the two independent tests provided the same apparent conclusion that N-hydroxy-PhIP-N2-glucuronide was the most important variable in predicting the level of PhIP-DNA adducts in the colon.


View this table:
[in this window]
[in a new window]
  		Table 4. Univariate linear model results from all variables for outcome related to DNA adduct levels

 
Linear regression analysis showed that both N-hydroxy-PhIP-N2-glucuronide levels in the urine and CYP1A2 activity were negatively correlated with the level of PhIP-DNA adducts in the colon. A higher level of N-hydroxy-PhIP-N2-glucuronide in the urine and a rapid CYP1A2 phenotype were associated with lower levels of colon PhIP-DNA adducts (Table 5 ).


View this table:
[in this window]
[in a new window]
  		Table 5. Relationship between CYP1A2 phenotype, urinary N-OH-PhIP-N2-glucuronide and colon DNA adduct levels

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
This study has allowed, for the first time, a comprehensive assessment of PhIP metabolism and DNA adduct formation in humans at a dietary relevant dose of PhIP. The use of radiolabeled PhIP and AMS technology allowed for the quantification of urinary metabolites and colon DNA adducts at levels that are consistent with a typical dietary exposure. The findings from this pilot study are consistent with earlier data showing that PhIP urinary metabolites and DNA adducts are formed in significant quantities even from a low-dose exposure of PhIP (17, 26). The data suggest that there is a significant correlation between urinary N-hydroxy-PhIP-N2-glucuronide levels and colon DNA adducts. Interpretation of the results from this study must take into account that the study population was small and that the human volunteers were cancer patients undergoing colorectal cancer surgery, which could have influenced the disposition of PhIP in these subjects.

Six of the 12 PhIP metabolites were identified as glucuronide conjugates, indicating that glucuronidation plays a significant role in the metabolism of PhIP. The identification of N-hydroxy-PhIP-N2-glucuronide as the major urinary metabolite in all 10 subjects is consistent with earlier studies showing UGT1A1-mediated glucuronidation as being a major pathway in the biotransformation of PhIP (35). The presence of this metabolite also serves as an indirect indicator of PhIP bioactivation because formation of the CYP1A2-mediated reactive intermediate N-hydroxy-PhIP is a prerequisite step to forming N-hydroxy-PhIP-N2-glucuronide (15, 16). These results are contrary to what has been reported for rodents. In both rats and mice, N-hydroxy-PhIP-N2-glucuronide is a minor urinary metabolite. The major metabolite in the rodent is 4'-PhIP-sulfate, indicating that hydroxylation at the 4' position (a detoxification step) is more prevalent in rodents than in humans (36, 37). This could be due to differences in substrate selectivity and oxidation rates of the different CYP450 isozymes between humans and the rodent model. These differences between humans and rodents support the necessity for more human studies to determine if there is an association between specific metabolic pathways, DNA adducts, and carcinogenic outcome.

The finding that glucuronidation is a major detoxification pathway in the biotransformation of PhIP is significant because the capacity to glucuronidate N-hydroxy-PhIP can vary greatly among individuals due to genetic polymorphisms in the UGT1A1 gene. The most notable polymorphisms are variants in the UGT1A1 gene that result in significant down-regulation of UGT1A1 activity. The most prevalent polymorphism is characterized by an allelic variant in the UGT1A1 gene, which contains an additional (TA) dinucleotide repeat in the "A(TA)nTAA" box region of the promoter (38). Wild-type UGT1A1 activity is associated with six repeats, whereas the variant allele contains seven TA repeats (UGT1A1*28). Significant down-regulation of UGT1A1 activity results when this variant is present in both alleles (homozygous). The frequency of occurrence is relatively high at 10% to 12% of the general population. There is evidence to suggest that individuals with the UGT1A1*28 genotype may be at greater risk for cancer from exposure to heterocyclic amines that are conjugated by UGT1A1 because their ability to detoxify these compounds would be diminished (39). For example, a recent study has reported a correlation between the UGT1A1*28 polymorphism and a decreased ability to glucuronidate and detoxify N-hydroxy-PhIP in human liver microsomes (21).

In the current study, seven of the nine individuals that were genotyped for the UGT1A1*28 polymorphism were heterozygous (6 of 7) for the "A(TA)nTAA" repeat. The remaining two subjects were homozygous wild-type (6 of 6). Previous studies have shown that there is no significant difference in UGT1A1 activity between the wild-type and the heterozygous variant (33, 34). Only individuals possessing the homozygous variant (7 of 7) display significant down-regulation of UGT1A1 activity. Therefore, due to the lack of significant UGT1A1 genotype variation and the homogeneity of the study population, UGT1A1 genotype would not be expected to influence the metabolism or the DNA adduct profiles of these individuals. Additional experiments, using a larger study population, are needed to determine the role of UGT1A1 activity on PhIP-DNA adduct formation.

The differences in urinary PhIP metabolite ratios, relative metabolite excretion rates, and DNA and protein adducts between the study subjects suggest that interindividual phenotypic variation of specific enzymes associated with PhIP biotransformation may be contributing to these observed variations. Although it is difficult to make any definite conclusions from the data due to the small sample size, several trends in metabolite excretion rates, DNA adduct levels, and enzyme phenotypes were observed. Subjects 1, 4, and 7, who were categorized as having a rapid CYP1A2 phenotype, had the lowest level of [14C]PhIP bound to colon DNA. These subjects also had the fastest excretion rate and the highest levels of urinary N-hydroxy-PhIP-N2-glucuronide after 24 hours of collection, suggesting that detoxification of N-hydroxy-PhIP predominated over bioactivation. These observations agree with the linear regression analysis that showed that both N-hydroxy-PhIP-N2-glucuronide and CYP1A2 activity were negatively correlated to colon DNA adducts. Furthermore, the univariate analysis showed that N-hydroxy-PhIP-N2-glucuronide levels and CYP1A2 phenotype were also the most important variables in predicting colon DNA adduct levels.

Subjects 8 and 10 also had rapid excretion rates of N-hydroxy-PhIP-N2-glucuronide, although these individuals were categorized as having a slow CYP1A2 phenotype. These two subjects, however, did have a UGT1A3*3 genotype,4 which is associated with increased expression of UGT1A3 (40). The increased expression of UGT1A3 could have contributed to an increase in the formation of N-hydroxy-PhIP-N2-glucuronide (35). In another observation, subject 6 had the highest level of PhIP macromolecular adducts in all three end points (DNA, total protein, and whole tissue) and was the only subject with both NAT2 and SULT1A1 rapid phenotypes. Statistical analysis, however, indicated that there was no correlation (P < 0.05) between the NAT2 or SULT1A1 phenotype and DNA adduct levels. Furthermore, the differences among each individual in the time the colon tissue was harvested after [14C]PhIP exposure and the relative rate of DNA repair could have influenced DNA adduct levels. Further study is needed to determine if these observations are relevant to human cancer risk. Other variables that were excluded from analysis, due to the lack of relevance to PhIP metabolite levels and DNA adducts, were CYP1A1, NAT1, and glutathione S-transferase genotypes (data not shown).

The finding that colon DNA adducts were lower in subjects with a rapid CYP1A2 phenotype and a higher percentage of urinary N-hydroxy-PhIP-N2-glucuronide suggests that detoxification by glucuronidation predominated over bioactivation in these individuals. This was somewhat unexpected because Lang et al. (23) reported a correlation between rapid CYP1A2 and rapid NAT2 activity, with a higher incidence of colon cancer among individuals who consume heterocyclic amines in their diet. The differences between the two studies could be because Lang et al. did not know the precise exposure level of PhIP, whereas in this current study the exact PhIP dose was known. It is also possible that other unknown factors in the diet could have been linked to the carcinogenic outcome in the Lang et al. study. Furthermore, differences in glucuronidation activity among the sample population in the Lang et al. study were not reported. In support of the current study, Sachse et al. (41) reported that CYP1A2 activity was lower in colon cancer patients compared with controls. The low levels of adducts and high percentage of N-hydroxy-PhIP-N2-glucuronide observed in rapid CYP1A2 individuals seen in this present study could partially be explained by the differences in the Km and Vmax values for CYP1A2 and UGT1A1 as well as the phase II activation enzymes (i.e., acetyltransferase and/or sulfotransferase). A high percentage of N-hydroxy-PhIP-N2-glucuronide indicates that the reactive intermediate N-hydroxy-PhIP was detoxified by glucuronidation at a faster rate compared with conjugation by acetyltransferase and/or sulfotransferase, which results in further activation to the DNA-binding species. Therefore, it can be postulated that individuals with compromised UGT activity may be at greater risk from exposure to PhIP than individuals with normal or elevated levels of UGT because their ability to detoxify PhIP will be diminished. These results are consistent with the present understanding of PhIP metabolism (42).

Based on the above observations and from the statistical analysis of the data, it was determined that, out of all the variables investigated, N-hydroxy-PhIP-N2-glucuronide was the best predictor of colon DNA adducts. The subjects with a high percentage of N-hydroxy-PhIP-N2-glucuronide in their urine had the lowest level of PhIP-DNA adducts in their colon. This is the first time a urinary metabolite profile has been linked to a genotoxic end point in humans. These conclusions must be made with caution, however, because they are based on a small study group that may not be representative of the general population. Nevertheless, this pilot study has provided some insight into the disposition of PhIP in a human population at a dietary relevant dose and has served as a basis for continual study to determine if N-hydroxy-N2-glucuronide can serve as a reliable urinary biomarker to predict an individual's propensity to form colon DNA adducts.


   Acknowledgments
 
Grant support: National Cancer Institute grants CA55861, CA55751, CA58697; Environmental Protection Agency grant R825280; and U.S. Army grant MM4559FLB and RR13461. This work was done under the auspices of the U.S. Department of Energy by Lawrence Livermore National Laboratory under contract no. W-7405-ENG-48.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


   Footnotes
 
4 Unpublished data. Back

Received 5/ 1/06. Revised 8/ 3/06. Accepted 8/18/06.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Sugimura T, Wakabayashi K. Mutagens and carcinogens in foods. In: Pariza MW, editor. Mutagens and carcinogens in the diet. New York: Wiley-Liss; 1990. p. 1–18.
  2. Wakabayashi K, Nagao M, Esumi H, Sugimura T. Food-derived mutagens and carcinogens. Cancer Res 1992;52:2092–8s.
  3. Felton JS, Knize MG, Shen NH, et al. The isolation and identification of a new mutagen from fried ground beef: 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP). Carcinogenesis 1986;7:1081–6.[Abstract/Free Full Text]
  4. Sinha R, Rothman N, Brown ED, et al. High concentrations of the carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) occur in chicken but are dependent on the cooking method. Cancer Res 1995;55:4516–9.[Abstract/Free Full Text]
  5. Ito N, Hasegawa R, Sano M, et al. A new colon and mammary carcinogen in cooked food, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP). Carcinogenesis 1991;12:1503–6.[Abstract/Free Full Text]
  6. Shirai T, Sano M, Tamano S, et al. The prostate: a target for carcinogenicity of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) derived from cooked foods. Cancer Res 1997;57:195–8.[Abstract/Free Full Text]
  7. Esumi H, Ohgaki H, Kohzen E, Takayama S, Sugimura T. Induction of lymphoma in CDF1 mice by the food mutagen, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. Jpn J Cancer Res 1989;80:1176–8.[CrossRef]
  8. Dooley KL, Von Tungeln LS, Bucci T, Fu PP, Kadlubar FF. Comparative carcinogenicity of 4-aminobiphenyl and the food pyrolysates, Glu-P-1, IQ, PhIP, and MeIQx in the neonatal B6C3F1 male mouse. Cancer Lett 1992;62:205–9.[CrossRef][Medline]
  9. Sinha R, Kulldorff M, Chow WH, Denobile J, Rothman N. Dietary intake of heterocyclic amines, meat-derived mutagenic activity, and risk of colorectal adenomas. Cancer Epidemiol Biomarkers Prev 2001;10:559–62.[Abstract/Free Full Text]
  10. Zheng W, Gustafson DR, Sinha R, et al. Well-done meat intake and the risk of breast cancer. J Natl Cancer Inst 1998;90:1724–9.[Abstract/Free Full Text]
  11. Edwards RJ, Murray BP, Murray S, et al. Contribution of CYP1A1 and CYP1A2 to the activation of heterocyclic amines in monkeys and humans. Carcinogenesis 1994;15:829–36.[Abstract/Free Full Text]
  12. Boobis AR, Lynch AM, Murray S, et al. CYP1A2-catalyzed conversion of dietary heterocyclic amines to their proximate carcinogens is their major route of metabolism in humans. Cancer Res 1994;54:89–94.[Abstract/Free Full Text]
  13. Buonarati MH, Turteltaub KW, Shen NH, Felton JS. Role of sulfation and acetylation in the activation of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine to intermediates which bind DNA. Mutation Res 1990;245:185–90.[Medline]
  14. Ozawa S, Chou H-C, Kadlubar FF, Nagata K, Yamazoe Y, Kato R. Activation of 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5-b]pyridine by cDNA-expressed human and rat arylsulfotransferases. Jpn J Cancer Res 1994;85:1220–8.[CrossRef]
  15. Alexander J, Wallin H, Rossland OJ, et al. Formation of a glutathione conjugate and a semistable transportable glucuronide conjugate of N2-oxidized species of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in rat liver. Carcinogenesis 1991;12:2239–45.[Abstract/Free Full Text]
  16. Kaderlik KR, Mulder GJ, Turesky RJ, et al. Glucuronidation of N-hydroxy heterocyclic amines by human and rat liver microsomes. Carcinogenesis 1994;15:1695–701.[Abstract/Free Full Text]
  17. Malfatti MA, Kulp KS, Knize MG, et al. The identification of [2-14C]2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine metabolites in humans. Carcinogenesis 1999;20:705–13.[Abstract/Free Full Text]
  18. Stillwell WG, Kidd LCR, Wishnok JS, Tannenbaum SR, Sinha R. Urinary excretion of unmetabolized and phase II conjugates of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline in humans: relationship to cytochrome P4501A2 and N-acetyltransferase activity. Cancer Res 1997;57:3457–64.[Abstract/Free Full Text]
  19. Stillwell WG, Sinha R, Tannenbaum SR. Excretion of the N2-glucuronide conjugate of 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5-b]pyridine in the urine and its relationship to CYP1A2 and NAT2 activity levels in humans. Carcinogenesis 2002;23:831–8.[Abstract/Free Full Text]
  20. Sinha R, Rothman N, Mark SD, et al. Lower levels of urinary 2-amno-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx) in humans with higher CYP1A2 activity. Carcinogenesis 1995;16:2859–61.[Abstract/Free Full Text]
  21. Girard H, Thibaudeau J, Court MH, et al. UGT1A1 polymorphisms are important determinants of dietary carcinogen detoxification in the liver. Hepatology 2005;42:448–57.[CrossRef]
  22. Baranczewski P, Moller L. Relationship between content and activity of cytochrome P450 and induction of heterocyclic amine DNA adducts in human liver samples in vivo and in vitro. Cancer Epidemiol Biomarkers Prev 2004;13:1071–8.[Abstract/Free Full Text]
  23. Lang NP, Butler MA, Massengill J, et al. Rapid metabolic phenotypes for acetyltransferase and cytochrome P4501A2 and putative exposure to food-borne heterocyclic amines increases the risk for colorectal cancer or polyps. Cancer Epidemiol Biomarkers Prev 1994;3:675–82.[Abstract]
  24. Turteltaub KW, Felton JS, Gledhill BL, et al. Accelerator mass spectrometry in biomedical dosimetry: relationship between low-level exposure and covalent binding of heterocyclic amine carcinogens to DNA. Proc Natl Acad Sci U S A 1990;87:5288–92.[Abstract/Free Full Text]
  25. Vogel JS, Turteltaub KW, Finkel RC, Nelson DE. Accelerator mass spectrometry—isotope quantification at attomole sensitivity. Anal Chem 1995;67:A353–9.[Medline]
  26. Dingley KH, Curtis KD, Nowell S, Felton JS, Lang NP, Turteltaub KW. DNA and protein adduct formation in the colon and blood of humans after exposure to a dietary-relevant dose of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. Cancer Epidemiol Biomarkers Prev 1999;8:507–12.[Abstract/Free Full Text]
  27. Frantz CE, Bangerter C, Fultz E, Mayer KM, Vogel JS, Turteltaub KW. Dose-response studies of MeIQx in rat liver and liver DNA at low doses. Carcinogenesis 1995;16:367–73.[Abstract/Free Full Text]
  28. Frame LT, Ozawa S, Nowell S, et al. A simple colorimetric assay for phenotyping the major human thermostable phenol sulfotransferase (SULT1A1) using platelet cytosols. Drug Metab Dispos 2000;28:1063–8.[Abstract/Free Full Text]
  29. Butler MA, Iwasaki M, Guengerich FP, Kadlubar FF. Human cytochrome P-450PA (P-4501A2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc Natl Acad Sci U S A 1989;86:7696–700.[Abstract/Free Full Text]
  30. Lang NP, Nowell S, Malfatti MA, et al. In vivo human metabolism of [2-14C]2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP). Cancer Lett 1999;143:135–8.[CrossRef][Medline]
  31. Butler MA, Lang NP, Young JF, et al. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics 1992;2:116–27.[Medline]
  32. Frame LT, Gatlin TL, Kadlubar FF, Lang NP. Metabolic differences and their impact on human disease: sulfotransferase and colorectal cancer. Environ Toxicol Pharmacol 1997;4:277–81.
  33. Innocenti F, Grimsley C, Das S, et al. Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups. Pharmacogenetics 2002;12:725–33.[CrossRef][Medline]
  34. Lampe JW, Bigler J, Horner NK, Potter JD. UDP-glucuronosyltransferase (UGT1A1*28 and UGT1A6*2) polymorphisms in Caucasians and Asians: relationship to serum bilirubin concentrations. Pharmacogenetics 1999;9:341–9.[Medline]
  35. Malfatti MA, Felton JS. Human UDP-glucuronosyltransferase 1A1 is the primary enzyme responsible for the N-glucuronidation of N-hydroxy-PhIP in vitro. Chem Res Toxicol 2004;17:1137–44.[CrossRef][Medline]
  36. Buonarati M, Roper M, Morris C, Happe J, Knize M, Felton J. Metabolism of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in mice. Carcinogenesis 1992;13:621–7.[Abstract/Free Full Text]
  37. Langouet S, Paehler A, Welti DH, Kerriguy N, Guillouzo A, Turesky RJ. Differential metabolism of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in rat and human hepatocytes. Carcinogenesis 2002;23:115–22.[Abstract/Free Full Text]
  38. Bosma PJ, Chowdhury JR, Bakker C, et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 1995;333:1171–5.[Abstract/Free Full Text]
  39. Minors JO, McKinnon RA, Mackenzie PI. Genetic polymorphisms of UDP-glucuronosyltransferase and their functional significance. Toxicology 2002;181–2:453–6.
  40. Iwai M, Maruo Y, Ito M, Yamamoto K, Sato H, Takeuchi Y. Six novel UDP-glucuronosyltransferase (UGT1A3) polymorphisms with varying activity. J Hum Genet 2004;49:123–8.[CrossRef][Medline]
  41. Sachse C, Bhambra U, Smith G, et al. Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium, and influence on caffeine metabolism. Br J Clin Pharmacol 2003;55:68–76.[CrossRef][Medline]
  42. Turesky RJ. Heterocyclic aromatic amine metabolism, DNA adduct formation, mutagenesis, and carcinogenesis. Drug Metab Dispos 2002;34:625–50.



This article has been cited by other articles:


Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
M. Cotterchio, B. A. Boucher, M. Manno, S. Gallinger, A. B. Okey, and P. A. Harper
Red Meat Intake, Doneness, Polymorphisms in Genes that Encode Carcinogen-Metabolizing Enzymes, and Colorectal Cancer Risk
Cancer Epidemiol. Biomarkers Prev., November 1, 2008; 17(11): 3098 - 3107.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. K. Creton, H. Zhu, and N. J. Gooderham
The Cooked Meat Carcinogen 2-Amino-1-Methyl-6-Phenylimidazo[4,5-b]Pyridine Activates the Extracellular Signal Regulated Kinase Mitogen-Activated Protein Kinase Pathway
Cancer Res., December 1, 2007; 67(23): 11455 - 11462.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
R. W. Dellinger, G. Chen, A. S. Blevins-Primeau, J. Krzeminski, S. Amin, and P. Lazarus
Glucuronidation of PhIP and N-OH-PhIP by UDP-glucuronosyltransferase 1A10
Carcinogenesis, November 1, 2007; 28(11): 2412 - 2418.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
R. J. Turesky, J.-M. Yuan, R. Wang, S. Peterson, and M. C. Yu
Tobacco Smoking and Urinary Levels of 2-Amino-9H-Pyrido[2,3-b]Indole in Men of Shanghai, China
Cancer Epidemiol. Biomarkers Prev., August 1, 2007; 16(8): 1554 - 1560.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Brown, E. M. Tompkins, D. J. Boocock, E. A. Martin, P. B. Farmer, K. W. Turteltaub, E. Ubick, D. Hemingway, E. Horner-Glister, and I. N.H. White
Tamoxifen Forms DNA Adducts in Human Colon after Administration of a Single [14C]-Labeled Therapeutic Dose
Cancer Res., July 15, 2007; 67(14): 6995 - 7002.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Malfatti, M. A.
Right arrow Articles by Turteltaub, K. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Malfatti, M. A.
Right arrow Articles by Turteltaub, K. W.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online